Nephrology Therapeutics

1. List of Afinitor drug patents

Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib

AFINITOR's oppositions filed in EPO
AFINITOR Litigations
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131 NOVARTIS Cancer treatment
Nov, 2025

(2 years from now)

Do you want to check out AFINITOR patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

Market Authorisation Date: 30 March, 2009

Dosage: TABLET;ORAL

How can I launch a generic of AFINITOR before it's patent expiration?
More Information on Dosage

AFINITOR family patents

14

Norway

14

Japan

12

European Union

10

United States

10

Israel

9

Lithuania

8

Spain

8

Russia

7

Hong Kong

7

China

7

Portugal

6

Denmark

6

Cyprus

6

Slovenia

5

Czech Republic

5

Poland

5

Slovakia

3

Canada

3

Korea, Republic of

3

Mexico

3

Luxembourg

2

United Kingdom

2

Taiwan

1

Brazil

1

New Zealand

1

Australia

1

South Africa

1

Hungary

2. List of Anjeso drug patents

Treatment: Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881663 BAUDAX Method of treating pain in elderly patients with mild renal impairment
Mar, 2039

(15 years from now)

Do you want to check out ANJESO patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ANJESO family patents

8

United States

2

Korea, Republic of

2

China

2

Japan

2

Australia

2

European Union

1

Canada

3. List of Avycaz drug patents

Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally...

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(2 years from now)

Do you want to check out AVYCAZ patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
New Patient Population (NPP) Dec 20, 2025
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 2024-02-26

Market Authorisation Date: 25 February, 2015

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

6

United States

2

Poland

2

Japan

2

ME

2

France

2

Australia

1

Spain

1

Austria

1

Hong Kong

1

Turkey

1

Denmark

AP

1

AP

1

Czech Republic

1

Germany

1

China

YU

1

Yugoslavia

1

Brazil

1

Canada

1

Ukraine

1

Morocco

1

Estonia

1

Argentina

EA

1

EA

OA

1

OA

1

Norway

1

New Zealand

1

Croatia

1

Korea, Republic of

1

Israel

1

Portugal

1

Taiwan

1

Mexico

1

Costa Rica

1

Ecuador

1

Algeria

1

Bulgaria

1

South Africa

1

Slovakia

1

Slovenia

1

Hungary

1

European Union

4. List of Cabometyx drug patents

Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma; Treatment of a...

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use
Sep, 2024

(1 year, 3 months from now)

US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
Apr, 2037

(13 years from now)

US11098015 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions
Jul, 2031

(8 years from now)

Do you want to check out CABOMETYX patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's patent expiration?
More Information on Dosage

CABOMETYX family patents

67

United States

22

Japan

14

Australia

13

European Union

12

Korea, Republic of

9

Taiwan

8

Spain

7

China

7

New Zealand

6

Hong Kong

6

Denmark

6

Canada

5

Poland

5

Croatia

5

Slovenia

EA

4

EA

4

Portugal

3

Austria

3

Singapore

3

Argentina

3

Cyprus

3

Israel

3

Mexico

2

Brazil

2

South Africa

2

Hungary

1

RS

1

Russia

1

Morocco

1

San Marino

1

Netherlands

1

Lithuania

1

Luxembourg

5. List of Cerdelga drug patents

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; Long-term treatment of adults with gaucher disease type 1 who ...

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888544 GENZYME CORP Methods for treating Gaucher disease
Dec, 2038

(15 years from now)

Do you want to check out CERDELGA patents from before 2022?

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's patent expiration?
More Information on Dosage

CERDELGA family patents

4

United States

1

Korea, Republic of

1

China

1

Russia

1

Israel

1

Canada

1

Brazil

1

Singapore

1

Colombia

1

Mexico

1

Japan

1

Australia

1

European Union

6. List of Defitelio drug patents

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...

DEFITELIO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11236328 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(9 years from now)

Do you want to check out DEFITELIO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 30, 2023

Drugs and Companies using DEFIBROTIDE SODIUM ingredient

Market Authorisation Date: 30 March, 2016

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DEFITELIO family patents

6

United States

4

Korea, Republic of

2

China

1

Italy

1

Spain

1

Russia

1

Hong Kong

1

Brazil

1

Israel

1

Canada

1

Singapore

1

India

1

Mexico

1

Japan

1

Australia

1

Denmark

1

European Union

7. List of Fosrenol drug patents

Treatment: Reduction of serum phosphate in patients with end stage renal disease

FOSRENOL's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions
Aug, 2024

(1 year, 2 months from now)

Do you want to check out FOSRENOL patents from before 2022?

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 26 October, 2004

Dosage: TABLET, CHEWABLE;ORAL

How can I launch a generic of FOSRENOL before it's patent expiration?
More Information on Dosage

FOSRENOL family patents

8

United States

5

Denmark

5

European Union

4

Spain

4

Poland

4

Cyprus

4

Portugal

4

Slovenia

3

Canada

EA

3

EA

3

Japan

3

Australia

2

Austria

2

Germany

2

China

2

Brazil

2

Norway

2

Korea, Republic of

2

South Africa

2

Hungary

IB

1

IB

1

Hong Kong

1

Iceland

1

Czech Republic

1

Singapore

1

Argentina

1

New Zealand

1

Peru

1

Israel

1

Taiwan

1

Mexico

1

Finland

8. List of Fotivda drug patents

Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2024

(10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504365 AVEO PHARMS NA
Nov, 2039

(16 years from now)

Do you want to check out FOTIVDA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: 2025-03-10

Market Authorisation Date: 10 March, 2021

Dosage: CAPSULE;ORAL

More Information on Dosage

FOTIVDA family patents

7

United States

6

Japan

3

European Union

2

Austria

2

Germany

2

Brazil

2

Canada

2

Norway

2

Australia

1

Spain

1

Hong Kong

1

Denmark

1

Poland

1

China

1

Russia

EA

1

EA

1

New Zealand

1

Korea, Republic of

1

Belgium

1

Chile

1

Israel

1

Taiwan

1

Mexico

1

Netherlands

1

South Africa

9. List of Gelnique drug patents

Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449173 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(6 years from now)

Do you want to check out GELNIQUE patents from before 2022?

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Dosage: GEL;TRANSDERMAL

How can I launch a generic of GELNIQUE before it's patent expiration?
More Information on Dosage

GELNIQUE family patents

5

United States

4

Mexico

2

Spain

2

Canada

2

Japan

2

European Union

1

Korea, Republic of

1

Germany

1

Russia

1

China

1

Brazil

1

South Africa

1

Australia

10. List of Gemtesa drug patents

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(7 years from now)

Do you want to check out GEMTESA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: 2024-12-23

Market Authorisation Date: 23 December, 2020

Dosage: TABLET;ORAL

More Information on Dosage

GEMTESA family patents

8

United States

3

Japan

3

Korea, Republic of

2

Dominican Republic

2

China

2

Costa Rica

1

Spain

1

Austria

1

Hong Kong

1

Denmark

1

RS

1

Poland

1

Brazil

1

Canada

1

Ukraine

1

Singapore

1

Morocco

1

Argentina

EA

1

EA

1

ME

1

Nicaragua

1

New Zealand

1

Honduras

1

Croatia

1

Cyprus

1

Peru

1

Chile

1

Israel

1

Portugal

1

El Salvador

1

Taiwan

1

Georgia

1

Mexico

1

Australia

1

Ecuador

1

South Africa

1

Colombia

1

Tunisia

1

Slovenia

1

European Union

11. List of Glyxambi drug patents

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...

GLYXAMBI's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

Do you want to check out GLYXAMBI patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Market Authorisation Date: 30 January, 2015

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's patent expiration?
More Information on Dosage

GLYXAMBI family patents

7

United States

3

Canada

3

European Union

2

China

2

Japan

2

Korea, Republic of

2

Mexico

1

Spain

1

Hong Kong

1

Philippines

1

Turkey

1

Denmark

1

RS

1

Poland

EA

1

EA

1

New Zealand

1

Croatia

1

Cyprus

1

Israel

1

Chile

1

Portugal

1

Australia

1

Lithuania

1

Slovenia

1

Hungary

12. List of Goprelto drug patents

Treatment: Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucou...

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016407 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US9867815 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10973811 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

Do you want to check out GOPRELTO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 2021-12-14

Market Authorisation Date: 14 December, 2017

Dosage: SOLUTION;NASAL

More Information on Dosage

13. List of Injectafer drug patents

Treatment: Method to treat ida in adults with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder weighing at least 40 kg by administering iv ferric carboxymaltose to give...

INJECTAFER's oppositions filed in EPO
INJECTAFER Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11123321 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(4 months from now)

US11291645 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478502 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(3 years from now)

US7754702 AM REGENT Methods and compositions for administration of iron
Feb, 2028

(4 years from now)

US11433091 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(3 years from now)

US8895612 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(3 years from now)

Do you want to check out INJECTAFER patents from before 2022?
Exclusivity Exclusivity Expiration
New Strength (NS) Apr 28, 2024
New Patient Population (NPP) Nov 19, 2024

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 25 July, 2013

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of INJECTAFER before it's patent expiration?
More Information on Dosage

INJECTAFER family patents

24

United States

6

European Union

5

Korea, Republic of

3

Spain

3

Hong Kong

3

Denmark

3

Canada

3

Cyprus

3

Portugal

2

Germany

2

China

2

Brazil

2

Norway

2

Japan

2

Jordan

2

Australia

2

Slovenia

1

Uruguay

1

Austria

1

Malaysia

1

Poland

1

Russia

1

Argentina

1

New Zealand

1

Peru

1

Israel

1

Taiwan

1

Mexico

1

South Africa

1

Lithuania

1

Saudi Arabia

1

Hungary

14. List of Inlyta drug patents

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advan...

INLYTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(11 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(13 years from now)

Do you want to check out INLYTA patents from before 2022?

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's patent expiration?
More Information on Dosage

INLYTA family patents

14

United States

5

Japan

4

European Union

2

Spain

2

Poland

2

China

2

Canada

2

Singapore

2

Korea, Republic of

2

Portugal

2

Taiwan

2

Mexico

2

Australia

2

Slovenia

2

Hungary

1

Hong Kong

1

Philippines

1

Malaysia

1

Turkey

1

Denmark

1

Russia

1

Brazil

EA

1

EA

1

New Zealand

1

Cyprus

1

Israel

15. List of Invokamet drug patents

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...

INVOKAMET's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(1 year, 10 months from now)

Do you want to check out INVOKAMET patents from before 2022?

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's patent expiration?
More Information on Dosage

INVOKAMET family patents

45

United States

14

Japan

11

European Union

10

China

9

Argentina

9

Taiwan

8

Canada

EA

8

EA

8

Australia

8

South Africa

7

Ukraine

6

Spain

5

Norway

5

New Zealand

5

Korea, Republic of

5

Ecuador

4

Malaysia

4

Iceland

YU

4

Yugoslavia

4

Brazil

4

Israel

4

Mexico

4

Costa Rica

3

Denmark

3

Poland

3

Croatia

3

Cyprus

3

Peru

3

Portugal

3

Slovenia

2

RS

2

Singapore

2

ME

2

Hungary

1

Uruguay

1

Panama

1

Hong Kong

1

Nicaragua

1

Honduras

1

Guatemala

1

Chile

1

El Salvador

1

Netherlands

1

Colombia

1

Lithuania

1

Luxembourg

16. List of Invokamet Xr drug patents

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...

INVOKAMET XR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(1 year, 10 months from now)

Do you want to check out INVOKAMET XR patents from before 2022?

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 20 September, 2016

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's patent expiration?
More Information on Dosage

INVOKAMET XR family patents

45

United States

14

Japan

11

European Union

10

China

9

Argentina

9

Taiwan

8

Canada

EA

8

EA

8

Australia

8

South Africa

7

Ukraine

6

Spain

5

Norway

5

New Zealand

5

Korea, Republic of

5

Ecuador

4

Malaysia

4

Iceland

YU

4

Yugoslavia

4

Brazil

4

Israel

4

Mexico

4

Costa Rica

3

Denmark

3

Poland

3

Croatia

3

Cyprus

3

Peru

3

Portugal

3

Slovenia

2

RS

2

Singapore

2

ME

2

Hungary

1

Uruguay

1

Panama

1

Hong Kong

1

Nicaragua

1

Honduras

1

Guatemala

1

Chile

1

El Salvador

1

Netherlands

1

Colombia

1

Lithuania

1

Luxembourg

17. List of Invokana drug patents

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 ...

INVOKANA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(7 years from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(1 year, 10 months from now)

Do you want to check out INVOKANA patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

Market Authorisation Date: 29 March, 2013

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's patent expiration?
More Information on Dosage

INVOKANA family patents

51

United States

16

Japan

12

China

12

European Union

11

Australia

10

Argentina

10

Taiwan

9

Canada

EA

9

EA

8

Ukraine

8

South Africa

7

Spain

7

New Zealand

6

Korea, Republic of

6

Ecuador

5

Malaysia

5

Brazil

5

Norway

5

Israel

5

Mexico

5

Costa Rica

4

Iceland

4

Denmark

4

Poland

YU

4

Yugoslavia

4

Singapore

4

Croatia

4

Cyprus

4

Peru

4

Portugal

4

Slovenia

3

RS

3

ME

3

Hungary

2

Uruguay

2

Hong Kong

2

Nicaragua

2

Guatemala

2

Chile

2

Colombia

2

Lithuania

1

Panama

1

Honduras

1

San Marino

1

El Salvador

1

Jordan

1

Netherlands

1

Luxembourg

18. List of Jardiance drug patents

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...

JARDIANCE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

Do you want to check out JARDIANCE patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Aug 18, 2024
M (M) Feb 24, 2025

Drugs and Companies using EMPAGLIFLOZIN ingredient

Market Authorisation Date: 01 August, 2014

Dosage: TABLET;ORAL

How can I launch a generic of JARDIANCE before it's patent expiration?
More Information on Dosage

JARDIANCE family patents

7

United States

3

Canada

3

European Union

2

China

2

Japan

2

Korea, Republic of

2

Mexico

1

Spain

1

Hong Kong

1

Philippines

1

Turkey

1

Denmark

1

RS

1

Poland

EA

1

EA

1

New Zealand

1

Croatia

1

Cyprus

1

Israel

1

Chile

1

Portugal

1

Australia

1

Lithuania

1

Slovenia

1

Hungary

19. List of Korsuva drug patents

Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7727963 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US8536131 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US10017536 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US7713937 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(4 years from now)

US10793596 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US7402564 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10138270 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US8217007 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US8486894 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(4 years from now)

US8236766 CARA THERAP Uses of synthetic peptide amides
Nov, 2027

(4 years from now)

US9334305 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US9359399 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

Do you want to check out KORSUVA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 23, 2026

Drugs and Companies using DIFELIKEFALIN ACETATE ingredient

NCE-1 date: 2025-08-23

Market Authorisation Date: 23 August, 2021

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

KORSUVA family patents

32

United States

3

Canada

3

Japan

3

Korea, Republic of

2

Malaysia

2

Russia

2

China

2

New Zealand

2

Israel

2

Mexico

2

Australia

2

South Africa

2

European Union

1

Spain

1

Hong Kong

1

Denmark

1

Poland

1

Brazil

1

Cyprus

1

Portugal

1

Lithuania

1

Slovenia

1

Hungary

20. List of Monoferric drug patents

Treatment: Method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney d...

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8815301 PHARMACOSMOS AS Stable iron oligosaccharide compound
Aug, 2029

(6 years from now)

Do you want to check out MONOFERRIC patents from before 2022?

Drugs and Companies using FERRIC DERISOMALTOSE ingredient

Market Authorisation Date: 16 January, 2020

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

MONOFERRIC family patents

8

United States

3

Denmark

3

China

3

European Union

2

Spain

2

RS

2

Poland

2

Croatia

2

Portugal

2

Lithuania

2

Slovenia

2

Hungary

1

Hong Kong

1

Philippines

1

Brazil

1

Canada

1

Ukraine

EA

1

EA

1

Japan

1

New Zealand

1

Korea, Republic of

1

Cyprus

1

Mexico

1

Australia

1

South Africa

21. List of Myrbetriq drug patents

Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Use in combination with the muscarinic antagonist solifenacin succinate for th...

MYRBETRIQ's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE44872 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(5 months from now)

US8835474 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(5 months from now)

US8772315 APGDI Pharmaceutical composition for treating overactive bladder
Oct, 2028

(5 years from now)

US10842780 APGDI Pharmaceutical composition for modified release
Sep, 2029

(6 years from now)

Do you want to check out MYRBETRIQ patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ before it's patent expiration?
More Information on Dosage

MYRBETRIQ family patents

12

United States

9

Japan

4

European Union

3

Spain

3

Denmark

3

Poland

3

China

3

Canada

3

Portugal

3

Slovenia

2

Russia

2

Brazil

2

Norway

2

Croatia

2

Korea, Republic of

2

Cyprus

2

Israel

2

Mexico

2

Australia

2

South Africa

2

Hungary

1

Austria

1

Hong Kong

1

Germany

1

New Zealand

1

Taiwan

1

Netherlands

1

Lithuania

1

Luxembourg

22. List of Nexavar drug patents

Treatment: Treatment of advanced renal cell carcinoma; Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; Treatment of unresec...

NEXAVAR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877933 BAYER HLTHCARE Thermodynamically stable form of a tosylate salt
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618141 BAYER HLTHCARE Aryl ureas with angiogenesis inhibiting activity
Feb, 2023

(3 months ago)

US9737488 BAYER HLTHCARE Pharmaceutical composition for the treatment of cancer
Sep, 2028

(5 years from now)

Do you want to check out NEXAVAR patents from before 2022?

Drugs and Companies using SORAFENIB TOSYLATE ingredient

Market Authorisation Date: 20 December, 2005

Dosage: TABLET;ORAL

How can I launch a generic of NEXAVAR before it's patent expiration?
More Information on Dosage

NEXAVAR family patents

12

United States

7

European Union

5

Japan

5

Korea, Republic of

4

Peru

3

Spain

3

Hong Kong

3

Denmark

3

China

3

Canada

3

Cyprus

3

Portugal

3

Australia

3

Slovenia

2

Malaysia

2

Poland

2

Brazil

2

Ukraine

2

Singapore

2

Morocco

2

Argentina

2

Norway

2

New Zealand

2

Croatia

2

Honduras

2

Guatemala

2

Israel

2

Taiwan

2

Mexico

2

Cuba

2

South Africa

1

Uruguay

1

Austria

1

Dominican Republic

1

Germany

1

Russia

1

Costa Rica

1

Ecuador

1

Tunisia

23. List of Normocarb Hf 25 drug patents

Treatment: Use as replacement solution, hemofiltration solution or hemodiafiltration solution in continuous renal replacement therapy

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7300674 DIALYSIS SUPS Sterile low bicarbonate dialysis concentrate solutions
Mar, 2023

(2 months ago)

Do you want to check out NORMOCARB HF 25 patents from before 2022?

Drugs and Companies using MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE ingredient

Market Authorisation Date: 26 July, 2006

Dosage: SOLUTION;INJECTION

More Information on Dosage

NORMOCARB HF 25 family patents

3

United States

2

Canada

1

Australia

1

European Union

24. List of Omontys drug patents

Treatment: Treatment of anemia due to chronic kidney disease

Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(11 months from now)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(3 years from now)

US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses
Jun, 2026

(3 years from now)

Do you want to check out OMONTYS patents from before 2022?

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Market Authorisation Date: 27 March, 2012

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage

OMONTYS family patents

21

United States

6

Japan

3

Korea, Republic of

3

European Union

2

China

2

Brazil

2

Canada

2

Ukraine

2

Singapore

EA

2

EA

2

Norway

2

New Zealand

2

Mexico

2

Australia

2

Costa Rica

2

South Africa

1

Spain

1

Hong Kong

1

Austria

1

Iceland

1

Denmark

AP

1

AP

1

Poland

1

Germany

YU

1

Yugoslavia

1

Morocco

OA

1

OA

1

ME

1

Croatia

1

Cyprus

1

Israel

1

Portugal

1

Georgia

1

Slovenia

25. List of Opana Er drug patents

Treatment: Dose modification for renal impairment

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8808737 ENDO PHARMS Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
Jun, 2027

(4 years from now)

Do you want to check out OPANA ER patents from before 2022?

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 22 June, 2006

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

OPANA ER family patents

5

United States

26. List of Rayaldee drug patents

Treatment: Treating secondary hyperparathyroidism in stage 3/4 chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level while avoiding pth oversup...

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154509 EIRGEN Methods for controlled release oral dosage of a vitamin D compound
Apr, 2028

(4 years from now)

US9925147 EIRGEN Method for treating secondary hyperparathyroidism in CKD
Apr, 2028

(4 years from now)

US9408858 EIRGEN Method for treating secondary hyperparathyroidism in CKD
Apr, 2028

(4 years from now)

US8207149 EIRGEN Method for treating secondary hyperparathyroidism in CKD
Apr, 2028

(4 years from now)

US9498486 EIRGEN Method for controlled release oral dosage of a vitamin D compound
Apr, 2028

(4 years from now)

Do you want to check out RAYALDEE patents from before 2022?

Drugs and Companies using CALCIFEDIOL ingredient

Market Authorisation Date: 17 June, 2016

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

RAYALDEE family patents

11

United States

6

Korea, Republic of

5

European Union

4

Hong Kong

4

Japan

3

Spain

3

Portugal

3

Denmark

2

Poland

2

China

2

Cyprus

2

Canada

2

Slovenia

1

Norway

27. List of Recarbrio drug patents

Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(6 years from now)

Do you want to check out RECARBRIO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2024
Generating Antibiotic Incentives Now (GAIN) Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 2028-07-16

Market Authorisation Date: 16 July, 2019

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

RECARBRIO family patents

4

United States

3

Japan

3

Lithuania

2

Spain

2

Hong Kong

2

Denmark

2

RS

2

Poland

2

China

2

Croatia

2

Korea, Republic of

2

Cyprus

2

Portugal

2

Ecuador

2

Netherlands

2

Slovenia

2

Hungary

2

European Union

1

Dominican Republic

1

Malaysia

1

Russia

1

Brazil

1

Canada

1

Ukraine

1

Morocco

1

Norway

1

ME

1

Nicaragua

1

Honduras

1

New Zealand

1

Israel

1

Mexico

1

Australia

1

Costa Rica

1

South Africa

1

Colombia

1

Luxembourg

28. List of Recorlev drug patents

Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage...

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(16 years from now)

US11278547 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(16 years from now)

Do you want to check out RECORLEV patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 30, 2028

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Dosage: TABLET;ORAL

More Information on Dosage

RECORLEV family patents

5

United States